Article information
Full text is only aviable in PDF
REFERENCES
[1]
J Barberà.
Nueva nomenclatura y clasificación de la hipertensión pulmonar.
Arch Bronconeumol, 38 (2002), pp. 3-9
[2]
Primary pulmonary hypertension. Executive summary from the World Symposium on Primary Pulmonary Hypertension,
[3]
E Yi, H Kim, H Ahn, J Strother, T Morris, E Masliah, et al.
Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study.
Am J Respir Crit Care Med, 162 (2000), pp. 1577-1586
[4]
S Lee, K Shroyer, N Markham, C Cool, N Voelkel, R Tuder.
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.
J Clin Invest, 101 (1998), pp. 927-934
[5]
J Lloyd, M Butler, T Foroud, P Conneally, J Phillips, J Newman.
Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension.
Am J Respir Crit Care Med, 152 (1995), pp. 93-97
[6]
W Nichols, D Koller, B Slovis, T Foroud, V Terry, N Arnold, et al.
Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32.
Nat Genet, 15 (1997), pp. 277-280
[7]
J Morse, A Jones, R Barst, S Hodge, K Wilhelmsen, T Nygaard.
Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.
Circulation, 95 (1997), pp. 2603-2606
[8]
J Newman, L Wheeler, K Lane, E Loyd, R Gaddipati, J Phillips, et al.
Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
N Engl J Med, 345 (2001), pp. 319-324
[9]
J Thomson, R Machado, M Pauciulo, N Morgan, M Humbert, G Elliott, et al.
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
J Med Genet, 37 (2000), pp. 741-745
[10]
N Morrell, X Yang, P Upton, K Jourdan, N Morgan, K Sheares, et al.
Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta and bone morphogenetic proteins.
[11]
R Trembath, J Thomson, R Machado, N Morgan, C Atkinson, I Winship, et al.
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
N Engl J Med, 345 (2001), pp. 325-334
[12]
M Yanagisawa, H Kurihara, S Kimura, K Goto, T Masaki.
A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels.
J Hypertens Suppl, 6 (1988), pp. 88-91
[13]
A Giaid, M Yanagisawa, D Langleben, R Michel, R Levy, H Shennib, et al.
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.
N Engl J Med, 328 (1993), pp. 1732-1739
[14]
B Rondelet, R van Beneden, F Kerbaul, S Motte, P Fesler, K McEntee, et al.
Expression of the serotonin 1b receptor in experimental pulmonary hypertension.
Eur Respir J, 22 (2003), pp. 408-412
[15]
R Channick, G Simonneau, O Sitbon, I Robbins, A Frost, V Tapson, et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Lancet, 358 (2001), pp. 1119-1123
[16]
O Sitbon, D Badesch, R Channick, A Frost, I Robbins, G Simonneau, et al.
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Chest, 124 (2003), pp. 247-254
[17]
N Galie, A Hinderliter, A Torbicki, T Fourme, G Simonneau, T Pulido, et al.
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
J Am Coll Cardiol, 41 (2003), pp. 1380-1386
[18]
L Du, C Sullivan, D Chu, A Cho, M Kido, P Wolf, et al.
Signaling molecules in nonfamilial pulmonary hypertension.
N Engl J Med, 348 (2003), pp. 500-509
[19]
C Sullivan, L Du, D Chu, A Cho, M Kido, P Wolf, et al.
Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.
Proc Natl Acad Sci USA, 100 (2003), pp. 12331-12336
[20]
A Dinh-Xuan, T Higenbottam, C Clelland, J Pepke-Zaba, G Cremona, A Butt, et al.
Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease.
N Engl J Med, 324 (1991), pp. 1539-1547
[21]
L Cea-Calvo, P Escribano, R Tello, M Gómez, J Delgado, C Sáenz.
Sildenafilo como sustituto de la prostaciclina subcutánea en la hipertensión pulmonar.
Arch Bronconeumol, 39 (2003), pp. 476-477
[22]
A Giaid, D Saleh.
Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.
N Engl J Med, 333 (1995), pp. 214-221
[23]
R Berger, R Geiger, J Hess, A Bogers, W Mooi.
Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease.
Am J Respir Crit Care Med, 163 (2001), pp. 1493-1499
[24]
R Tuder, C Cool, M Geraci, J Wang, S Abman, L Wright, et al.
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.
Am J Respir Crit Care Med, 159 (1999), pp. 1925-1932
[25]
V Roig, A Herrero, N de la Torre, E Hernández, J Aller, J Cabello.
Iloprost en la hipertensión pulmonar tromboembólica crónica.
Arch Bronconeumol, 40 (2004), pp. 326-328
[26]
J Yuan, A Aldinger, M Juhaszova, J Wang, J Conte, S Gaine, et al.
Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension.
Circulation, 98 (1998), pp. 1400-1406
[27]
C Cool, P Rai, M Yeager, D Hernández-Saavedra, A Serls, T Bull, et al.
Expression of human herpesvirus 8 in primary pulmonary hypertension.
N Engl J Med, 349 (2003), pp. 1113-1122
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
